BXRX =FDA DECISION on FEB.20
BXRX =MC $79 M -Cash $20 M / FDA DECISION ON FEB.20 for Non-Opioid Pain Drug / UNKNOWN Gem = 500%+ Upside
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”